ClinicalTrials.gg
CompletedNCT01371331OPTIONUpdated Nov 1, 2024

A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation

A Phase 4 interventional study of Tacrolimus granules in Kidney Transplantation, Heart Transplantation and Liver Transplantation, sponsored by Astellas Pharma Europe Ltd.. Completed at 10 sites in 6 countries. Open to participants aged 0 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Astellas Pharma Europe Ltd. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
0 Years to 12 Years
Sex
All
01

Study summary

The purpose of this study is to find out how much of Modigraf is absorbed and used in the body and how fast it leaves the body (Pharmacokinetics). The results will then help to decide how much Modigraf in future can be given safely to children and young people following transplantation.

Read the detailed description

The primary objective of this study is to determine the pharmacokinetics (PK) of tacrolimus following oral administration of Modigraf, after the first oral dose and at steady state in paediatric subjects undergoing de novo allograft transplantation.

02

Conditions studied

  • Kidney Transplantation
  • Heart Transplantation
  • Liver Transplantation

Keywords

  • Kidney Transplantation
  • Pharmacokinetics
  • Heart Transplantation
  • Liver Transplantation
03

In context

Lead sponsor

Astellas Pharma Europe Ltd. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is the recipient of a solid organ (liver, kidney or heart) transplant. Multiorgan transplants are acceptable as long as one of the organs transplanted is liver, kidney or heart

Exclusion criteria

Exclusion Criteria:

  • The subject has previously received another organ transplant (including liver, kidney or heart re-transplantation)
  • Subject has a high immunological risk, defined as a Panel Reactive Antibody (PRA) score >50% in the previous 6 months (only applicable for renal transplant recipients)
  • Cold ischemia time of the donor kidney greater than 30 hours (only applicable for renal transplant recipients)
  • Subject receives an AB0 incompatible donor organ
  • Subject has significant renal impairment, defined as having serum creatinine ≥230 μmol/l (≥2.6 mg/dl) pre-transplantation (not applicable for renal transplant recipients)
  • Subject has significant liver disease, defined as having elevated (ALT) and/or Asparate Aminotransferase (AST) and/or Total levels 3 times the upper value of the normal range during the 28 days prior to transplantation (not applicable for liver transplant recipients)
  • Subject with pulmonary vascular resistance greater than 4 Wood units which is unresponsive to treatment
  • Subjects with or a history of malignancy within the last 5 years
  • Subject has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer
  • Subject requires systemic medication for any indication other than transplantation
  • Recipient or donor known to be , or positive
  • Known allergy or intolerance to , macrolide antibiotics, basiliximab or tacrolimus
  • Subject is currently participating in another clinical trial and/or has been taking an drug in the 3 months prior to transplantation
  • Subject is unlikely to comply with the visits scheduled in the protocol
  • Subjects taking or requiring to be treated with medication or substances prohibited by this protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Tacrolimus granules

    oral

    Drug: Tacrolimus granules

Interventions

06

What researchers measure

Primary outcomes

  1. Determine AUCtau (area under the plasma concentration-time curve for a dosing interval)

    Time frame: on Day 1 and Day 7 (+/- 7 days)

  2. Determine Cmax (maximum concentration)

    Time frame: on Day 1 and Day 7 (+/- 7 days)

  3. Determine tmax (time to attain Cmax)

    Time frame: on Day 1 and Day 7 (+/- 7 days)

  4. Determine Ctrough (plasma concentration at the end of a dosing interval)

    Time frame: on Day 1 and Day 7 (+/- 7 days)

Secondary outcomes

  1. Rejection episodes

    Time frame: 14 days

  2. Patient survival

    Time frame: 14 days

  3. Graft survival

    Time frame: 14 days

  4. Assessment of safety through the evaluation of Adverse Events, laboratory parameters and vital signs

    Time frame: 14 days

07

Study locations

10 sites
  • Site 40
    Brussels, 1200, Belgium
  • Site: 60
    Bron Cedex, 69677, France
  • Site 31
    Hannover, 30625, Germany
  • Site 30
    Heidelberg, 69120, Germany
  • Site 50
    Warsaw, 04-730, Poland
  • Site 22
    Madrid, 28007, Spain
  • Site 20
    Madrid, 28046, Spain
  • Site 21
    Madrid, 28046, Spain
  • Site 10
    Birmingham, B4 6NH, United Kingdom
  • Site 13
    Manchester, M13 9WL, United Kingdom
08

References and documents

Publications

  • Webb NJA, Baumann U, Camino M, Frauca E, Undre N; OPTION Study Group. Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. Pediatr Transplant. 2019 Feb;23(1):e13328. doi: 10.1111/petr.13328. Epub 2019 Jan 21. PubMed 30665258 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2011 to primary completion in Feb 2015, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 10, 2011
StartActual
Jun 9, 2011
Primary completionActual
Feb 3, 2015
CompletionActual
Feb 3, 2015
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01371331
Responsible party
Sponsor
First posted
Jun 10, 2011
Start date
Jun 9, 2011
Primary completion
Feb 3, 2015
Completion
Feb 3, 2015
Last update
Nov 1, 2024

Study contacts

Senior Study Manager
study chair · Astellas Pharma Europe Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion